PSS22 - Secukinumab Significantly Reduces Work Impairment and Indirect Costs Compared To Ustekinumab and Etanercept In The United Kingdom
| Autor: | Warren, R, Halliday, A, Graham, CN, Gilloteau, I, Miles, L, Sherif, B, McBride, D |
|---|---|
| Zdroj: | In Value in Health October-November 2017 20(9):A804-A804 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect